Novel nanoemulsion vaccine has great advantages in disease tactic therapy. These set effects are minimized by properties such as unique tumor chopism, the identification of specific tactics, and the low systemic toxicity. We anticipate that the protocol will provide technical and theoretical clues for the future development of novel T-cell ectype peptide mucosal vaccines.
Begin by mixing one milligram of monophosphorol lipid A with 100 microliters of DMSO. Vortex for five minutes and leave it to dissolve for four hours at room temperature. Quantitatively add TWEEN 80 and I-OVA.
Mix the components and add squalene. Next, add 100 microliters of MPLA solution to the prepared mixture. To prepare the nano emulsion vaccine, add the mixed solution to water droplets at approximately 70%of the total volume and stir gently to obtain a transparent and easily flowing mixture.
For in vitro assays, start with reviving the BEAS2B epithelial cells. Turn the water bath on and adjust the temperature to 37 degrees Celsius. Thaw the frozen cell vials quickly in a water bath, tempered at 37 degrees Celsius.
After thawing, quickly pipette the cells into a 15 milliliter sterile centrifuge tube, and add two milliliters of the complete growth medium. Centrifuge the tube at 129 G for five minutes. Remove the supinatant and resuspend the cells in two milliliters of the complete growth medium.
After centrifuging the cells once again, remove the supinatant and add six milliliters of complete growth medium to resuspend the cells. Then transfer the cells to a T25 culture flask and incubate at 37 degrees Celsius in a 5%carbon dioxide incubator. Once the cell density reaches 80%to 90%discard the culture medium and wash the cells twice with two milliliters of PBS.
Add one milliliter of 0.25%tripsin to digest the cells for one to two minutes. When rounding of the cells is observed, immediately add four milliliters of the complete growth medium to neutralize the trypsin. Mix and aspirate the samples in a 15 milliliter sterile centrifuge tube.
Centrifuge the samples at 129 G for five minutes. Remove the supinatant and resuspend the cells in one milliliter of RPMI 1640 complete medium. Use 20 microliters of the cell suspension for cell counting and dilute the cells to one times 10 to the fifth cells per milliliter.
Then plate the BEAS2B cells at a density of one times 10 to the fourth cells per well in 96 well plates in 100 microliters of RPMI 1640 complete medium, and pre incubate the plates for 24 hours as demonstrated previously. At the end of the incubation, discard the supinatant and add 100 microliters of RPMI 1640 to each well of the 96 well plate. Add 100 microliters each of I-OVA nano emulsion, I-OVA mixed with BNE, and I-OVA pre-diluted with a complete growth medium at various final concentrations with BNE as a control and incubate for 24 hours at 37 degrees Celsius.
Once the incubation is complete, remove the medium, and transfer the plate to a dark place. Add 90 microliters of complete growth medium and 10 microliters of CCK8 solution to each well of the plate. Incubate the plate for two hours at 37 degrees Celsius and 5%carbon dioxide.
Measure the absorbance of each well at 450 nanometers using an enzyme labeled plate reader. Use 10 microliter pipette tips to perform nasal immunization of the mice with I-OVA, I-OVA plus BNE, and I-OVA NE for three days. Use BNE and PBA as the experimental control.
Afterward, cut approximately three millimeter thick samples of nasal tissues with scissors and place them in 4%paraformaldehyde. Remove the lung tissues and fix the nasal and whole lung tissues in 4%paraformaldehyde for 24 hours. TEM and AFM are used for the assessment of basic characteristics of the surface zeta potential and the particle size of the nano vaccine.
Particle sizes, polydispersity indexes, zeta potentials, and electrophoresis mobility of I-OVA NE in musin stability analyses are shown. The relative viability of BEAS2B cells is more than 80%in cultures exposed to different peptide concentrations of I-OVA, BNE+I-OVA, and I-OVA NE for 24 hours. The I-OVA EN group had no obvious mucosal toxicity, tissue damage, bleeding, or inflammatory cell infiltration.
The epithelial BEAS2B cells captured more FITC labeled I-OVA NE than that of its water solution. The sustained release effect of I-OVA NE in vitro was analyzed using the IV-IS system. I-OVA NE vaccine had a sustained release effect compared to the aqueous solution of I-OVA.
In the I-OVA NE group, the percent survival time is higher compared to other groups, and the tumor volume was significantly smaller, suggesting that it has a better preventive protection effect than the other groups. In the therapeutic model, the median survival time was significantly different between different groups. The tumor volume of the I-OVA NE group was significantly smaller than that in the I-OVA group.
Stirring the mixture evenly is important in this procedure. Otherwise it'll reduce the efficiency of nanovaccines.
